drugset / Trial / NCT02025803
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no available therapy likely to convey clinical benefit.
Timeline
- Start
- 2012-11
- Primary completion
- 2017-07-07
- Completion
- 2017-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 760 mg/m2 | Oral |
| Subject | TAS-114 | Unknown | 20 mg/m2 | Oral |
| Subject | TAS-114 | Unknown | 480 mg/m2 | Oral |